Velos, Inc. will introduce its Velos Volunteer web application at the American Medical Informatics Association (AMIA) 2012 Summit on Clinical Research Informatics in San Francisco, California on March 21 to 24. Velos Volunteer helps organizations enlist and manage future participants in clinical trials through a process-oriented, ethical, and compliant methodology.
"We are pleased to release Velos Volunteer to improve compliance and efficiency in the recruitment process for clinical trials and to support meaningful use of data from medical records," said John McIlwain, President of Velos.
Currently, most researchers, coordinators, and nurses maintain respondent contact information on paper, spreadsheets, and sundry databases. This inefficient process is often not fully compliant with existing rules and best practices for recruitment in clinical trials. For example, it is necessary to select volunteers fairly on a first-come, first-serve basis and eliminate bias. There is also an acute need for research sites to present recruitment capabilities and strategies to industry sponsors as well as evidence-based data measuring recruitment success and failure. Velos Volunteer provides metrics for enrollment and screening reporting to address these needs that are often otherwise not readily available. Ethical and compliant recruitment is also a great way to achieve meaningful use of medical records if supported by the proper systems.
"Velos Volunteer provides us with a sponsor-friendly recruitment dataset and uniform, audit-ready workflow throughout our entire recruiting process. We can load electronically large numbers of patients we identify as possible enrollment candidates from our clinical data repository and manage them through the same process," said Julie Eckstrand, Assistant Director–Clinical Support Services and Quality Management.
Velos Volunteer remedies these problems through a secure system that complies with institutional security, IRB and HIPAA requirements. The database and consent for storage of PHI is an IRB-approved protocol itself that is not limited to a specific study. System features include call tracking, script management, inclusion/exclusion criteria and response management, blacklisting, and messaging. The system also provides a platform to inform respondents of the risks and benefits on a one-on-one basis which facilitates adherence to good clinical practice. The system also incorporates workflow-based design to navigate based on the direction of conversation with respondents. In addition to addressing compliance and meaningful use needs, Velos Volunteer works the way recruiters work and reduces time spent performing redundant tasks.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.